Monday November 2, 03:33 AM Source: Indian Express Finance

Piramal Healthcare to launch 26 drugs

By Soma Das
The fifth largest domestic pharma company, Piramal Healthcare Ltd, plans to launch around 26 drugs in the current financial year. The launches make Piramal Healthcare top the list of 10 largest domestic pharma companies on the basis of revenue earned from new drug launches, as per data from ORG IMS. The company currently commands a market share of 4.1%, up from 3.7% last year. We plan to launch a total of 26 products in FY 10, Swati Piramal, director of strategic alliances and communications, Piramal Healthcare, told FE . A significant part of the portfolio would be from the derma vertical, meant for sensitive skin, and would be brought to the market from the derma specialty stable of Pierre Fabre, the third-largest pharma company of France. The Mumbai-based firm entered into a partnership with the French pharma major last year to launch a new dermo-cosmetic range, Ducray. When asked whether the company is open to further brand acquisitions in the potential high-growth area of aesthetic dermatology, Piramal said, We will keep bringing two to three products every year in the dermatology segment from our French partner Pierre Fabre. She said Piramal Healthcare s tie-up with the French firm is exclusive in nature and in this particular segment, the company is not considering more tie-ups presently. Of the 26 products, the company has already launched nine products in the first quarter and introduced nine more in the second quarter.

RECENT BUSINESS NEWS

RELATED NEWS

RSS FEEDS

All headlines to your personalized My Yahoo! page
(Learn about My Yahoo! and RSS)
  • All Business News
  • India Business News
  • World Business News
  • Personal Finance News
More Finance RSS Feeds




Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for BSE and NSE(when not logged-in) See also delay times for other exchanges.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Prior to execution of any security trade, you are advised to consult your authorized financial advisor to verify the accuracy of all information. Neither Yahoo! nor any independent provider is liable for any informational errors, incompleteness or delays or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found herein.